Stocklytics Platform
Asset logo for symbol DXCM
DexCom
DXCM73
$63.99arrow_drop_down40.66%-$43.86
High Quality
S&P500
Asset logo for symbol DXCM
DXCM73

$63.99

arrow_drop_down40.66%
Key Stats
Open$66.03
Prev. Close$107.85
EPS1.55
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range62.34
67.44
52 Week Range62.34
142.00
Ratios
EPS1.55
Fundamentals
Payout Ratio-
Industry average yield2.88%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

DXCMarrow_drop_up0.46%
US Healthcare Sectorarrow_drop_up0.23%
US Marketarrow_drop_down0.35%
check_circle
DXCM / Market
DXCM exceeded the US Market which returned -0.35% over the last twenty four hours.
check_circle
DXCM / Healthcare Sector
DXCM exceeded the US Healthcare sector which returned 0.23% over the last twenty four hours.

DexCom (DXCM) Statistics

DexCom Inc (DXCM) is a renowned medical technology company specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. With a focus on helping individuals with diabetes manage their condition more effectively, DexCom has become a market leader in this field. The company's CGM systems provide real-time glucose readings, allowing users to monitor and track their blood sugar levels continuously.
Valuation metrics play a crucial role in understanding a company's worth, and DexCom Inc is no exception. By analyzing factors such as the price-to-earnings ratio, price-to-sales ratio, and price-to-book ratio, investors can assess the relative value of DXCM stock. These metrics provide insights into how the market values the company and can guide investment decisions.
add DexCom  to watchlist

Keep an eye on DexCom

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has DexCom (DXCM) stock's performance compared to its sector and the market over the past year?
Over the past year, DexCom (DXCM) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 24.29%, DexCom has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 51.85%, it has fallen short of the market average. This comparison highlights DexCom 's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of DexCom (DXCM) stock?
The PE (Price to Earnings) ratio of DexCom (DXCM) is currently 41.28. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help
What is the EPS of DexCom (DXCM) stock?
The Earnings Per Share (EPS) for DexCom (DXCM), calculated on a diluted basis, is $1.55. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of DexCom (DXCM) stock?
The operating margin for DexCom (DXCM) is 10.98%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of DexCom (DXCM) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of DexCom (DXCM) is $1.03B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does DexCom (DXCM) have?
DexCom (DXCM) has a total debt of $2.54B. The net debt, which accounts for cash and cash equivalents against the total debt, is $1.74B.
email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level